Is Retatrutide FDA Approved? Approval Status and Timeline

No. Retatrutide is still in Phase 3 trials, Lilly hasn't sent the FDA its application, and no regulator anywhere has approved it. So as of September 2026, the answer to "is retatrutide FDA approved" is not yet: Lilly plans to submit in the first quarter of 2027, and the FDA's own review goals put a decision somewhere between late 2027 and early 2028.

Those dates rest on two things: Lilly's own filing plan and the review goals the FDA publishes for every new drug. A court fight over whether retatrutide is a drug or a biologic sits in the background, and it could change the paperwork.

Is retatrutide FDA approved for any use yet?

It isn't approved for anything, including weight loss, type 2 diabetes, sleep apnea and knee pain. Lilly's July 23, 2026 announcement calls retatrutide "an investigational molecule that cannot be legally sold or marketed for human use." The FDA puts it more bluntly on its page about unapproved weight-loss drugs, saying retatrutide is not a component of any FDA-approved drug and has "not been found safe and effective for any condition."

If you know it as GLP-3, it's the same molecule and the same answer. The same FDA page says retatrutide can't be used in compounding under federal law. The FDA says a compounded version of an approved GLP-1 drug can be appropriate in limited cases, such as when the approved drug isn't available. Retatrutide gets no such opening, so no compounding pharmacy can legally make it for you.

Here's how the path to this point has gone, from the court records and Lilly's releases:

Why isn't retatrutide approved yet?

Because nobody has asked the FDA to approve it. The agency can't review an application that doesn't exist, and Lilly's is still being put together.

The clinical side looks done. TRIUMPH-4 reported an average weight loss of 28.7% at 12 mg over 68 weeks in December 2025. TRIUMPH-1 followed in May 2026 with 28.3% on 12 mg at 80 weeks, and TRIUMPH-2 and TRIUMPH-3 came in at 20.8% and 22.6% on 12 mg in July. After those, Lilly said it had "the clinical data package to support global submissions" for obesity, knee osteoarthritis pain and obstructive sleep apnea. The per-trial detail lives on our retatrutide clinical trials page.

What was still missing in July was the manufacturing half. Lilly said it was still completing the Chemistry, Manufacturing, and Controls (CMC) data package a Biologics License Application requires, and would submit afterward. In plain terms, that file has to show the FDA that every batch comes out the same: the right molecule, at the right strength, free of contaminants, and stable on the shelf. Lilly's August 5, 2026 earnings report repeated the Q1 2027 target, still as a BLA.

How close is retatrutide to being approved?

Close enough to put rough dates on. The FDA publishes its review goals under the prescription drug user fee agreement (PDUFA), and they apply to both new drugs and new biologics.

Those are goals, and the FDA's target is to hit them for 90% of applications, not all of them. A major amendment during review can add 3 months. And "action" can mean a rejection letter asking for more data instead of an approval. Priority review goes to drugs the FDA judges a big improvement in treating a serious condition. The FDA makes that call within 60 days of receiving an application, and Lilly hasn't said whether it will ask for it.

Our read: an approval in 2027 needs a Q1 filing that stays on schedule plus a faster-than-standard review. On the plain standard clock, early 2028 is the likelier window, and getting a prescription filled at a pharmacy comes after that. The retatrutide release date page covers launch timing and what might delay it.

Why Lilly is suing the FDA over what retatrutide is

This one sounds like trivia, but it decides which kind of application Lilly files and how long retatrutide keeps competitors out.

Under FDA rules, a protein is an alpha amino acid chain "greater than 40 amino acids in size," and proteins are licensed as biologics. According to the district court's summary, Lilly told the FDA retatrutide has 41 amino acids: a 39-link backbone plus a 2-piece side chain. The FDA counted at most 40 alpha amino acids and 1 that isn't one, and on March 18, 2024 it classified retatrutide as a drug.

Lilly sued in September 2024. On September 30, 2025, a federal judge in Indiana agreed with the FDA that retatrutide isn't a protein by the rule's definition, but threw out the agency's finding that it isn't "analogous" to one and sent that question back to the FDA. Lilly appealed. The Seventh Circuit heard arguments on September 24, 2026 and took the case under advisement, then asked both sides for written briefs on whether it even has jurisdiction over this kind of appeal, due October 8, 2026.

The stakes are mostly about money and time. A biologic gets 12 years before a biosimilar copy can be approved, under federal law. A new chemical drug gets 5 years of exclusivity, per the FDA. Lilly's July release says it plans a Biologics License Application (BLA). We couldn't find a Lilly statement on how a loss in court would change the Q1 2027 plan, so treat that as an open question.

None of this is about whether retatrutide works or is safe. That part gets judged on the trial data, whichever form the application takes.

Is retatrutide approved in any country?

No country has approved it. On August 17, 2026, Lilly Canada put out a public safety notice saying retatrutide "has not yet been approved for human use by Health Canada or any other regulatory agency in the world." That covers the UK's MHRA, the European Medicines Agency, Australia's TGA and everyone else.

Lilly says its data supports global submissions, but the releases we read give a date only for the US. So if you've seen a site claiming retatrutide is approved in Mexico, Europe or somewhere else, it isn't, going by the company that makes it.

The same notice says Lilly has sued US companies selling black-market retatrutide and referred hundreds of illegal sellers to regulators and law enforcement worldwide.

What's sold online while you wait

Search for retatrutide and you'll find vials anyway. None of them are Lilly's. The FDA says it has warned companies for selling retatrutide with labels claiming it's a lab chemical not meant for people, while selling it straight to consumers with dosing instructions. It has also warned telehealth companies for marketing retatrutide and ingredient distributors for selling it to compounders. The agency's advice is not to buy these products, which it calls "of unknown quality."

The practical risks follow from that. No regulator has checked what's in a given vial, how much of it, or whether it's sterile, and dosing means doing your own math from a powder of unknown strength. If you're weighing an online seller anyway, our retatrutide for sale page covers how people check batch-specific test reports and the red flags worth walking away over. Whether owning or importing it is legal where you live is a separate question, answered on is retatrutide legal.

Legal ways to get retatrutide before approval

There are two: a clinical trial, or Lilly's expanded access program.

Clinical trials are the main one, but the doors are mostly shut. As of September 2026, a ClinicalTrials.gov search for retatrutide returns 33 records, and only 2 are recruiting. One of those 2 is a small study in China run by a company that isn't Lilly. The other is SYNERGY-Outcomes, a Lilly trial in adults with fatty liver disease (MASLD) who are at higher risk of serious liver problems. In a placebo-controlled trial, you might not get the drug at all.

Expanded access is the second, and it's narrow. Lilly posted a single-patient program in June 2026 (NCT07629401) for adults whose BMI is still 35 or more after sticking with the highest available dose of an approved weight-loss drug, and who have at least 2 serious or life-threatening obesity-related complications. You also have to be unable to join a trial. Your doctor makes the request through the Lilly Answers Center; Lilly asks patients not to contact it directly. Availability depends on where you live and on supply.

If you don't fit either, the approved options include tirzepatide (Zepbound) and semaglutide (Wegovy). Our read: with the earliest likely approval about a year away, starting an approved drug now and asking your doctor about switching later is a real option, and how to get retatrutide walks through all three routes.

The next dates to watch are the October 8 court briefs and, after that, word that the FDA has accepted Lilly's application, due about 60 days after it files. We log each one on the retatrutide news page.